Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPAM Systems Inc (EPAM) vs Novavax Inc (NVAX) Price & Performance

EPAM Systems IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

EPAM Systems Inc vs Novavax Inc — how do they compare? EPAM Systems Inc trades at $99.01 (market cap $5.15B), while Novavax Inc trades at $7.96 (market cap $1.31B). The key difference: EPAM Systems Inc is far larger — about 3.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.

EPAMNVAX
Market Cap
$5.15B$1.31B
Sector
TechnologyHealth
52-Week High
$221.40$11.19
52-Week Low
$76.04$6.22
Enterprise Value
$4.52B$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPAM Systems Inc

EPAM trades at $98.20, up 0.85% on the day, but remains in a bearish technical trend with support near $96 and resistance at $99. The company reported strong Q2 2026 earnings of $3.38 per share, beating estimates, but lowered its full-year revenue guidance due to slower North American growth. Valuation metrics appear attractive with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net income margin of 7.15%.

The outlook is mixed: analyst consensus is bullish with a $117.27 price target, but near-term headwinds from reduced revenue guidance and bearish technical signals pose risks. The stock offers value based on fundamentals, but investor sentiment is cautious following the guidance cut, requiring close monitoring of North American demand trends and AI partnership execution for sustained upside.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About EPAM Systems Inc

EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.

Read more on EPAM

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX